Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: A review

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 4, 2004, Pages 244-253

  Hansen, Birgitte R ^a   Haugaard, Steen B ^a   Iversen, Johan ^a   Nielsen, Jens Ole ^a   Andersen, Ove ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; HYDROXYUREA; INSULIN; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; DRUG MEGADOSE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; METABOLIC DISORDER; ORAL GLUCOSE TOLERANCE TEST; RETROSPECTIVE STUDY; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 2642559514     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410019381     Document Type: Review

References (69)

1. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 228-37.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8.
3. Boufassa F, Dulioust A, Lascaux AS, Meyer L, Boue F, Delfraissy JF, et al. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials 2001; 2: 339-45.
4. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study Lancet 2001; 357: 592-8.
5. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14: 37-49.
6. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726-35.
7. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidaemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
8. Lafeuillade A, Jolly P, Chadapaud S, Hittinger G, Lambry V, Philip G. Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens. J Acquir Immune Defic Syndr 2003; 33: 544-6.
9. van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001; 15: 847-55.
10. Carr. A. Cardiovascular risk factors in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 34(Suppl 1): S73-8.
11. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study, AIDS 2003; 17: 1179-93.
12. Boyd M, Bien D, van Warmerdarn P, Hassink E, Srasuebkul P, Chomchey, N, et al. Lipodystrophy in patients switched to indinavir/rironavir 800/100 mg BID and efavirenz 600 mg QD after failing nucleoside combination therapy: a prospective, 48-week observational sub-study of HIV-NAT 009. (abstract 738). Programmes and abstracts of the 10th conference on retroviruses and opportunistic infections (Boston), 2003.
13. Maggiolo F, Quinzan G, Gregis G, Ripamonti D, Ravasio L, Suter F. Thymidine analogues affect metabolic parameters: preliminary results of a randomized, controlled study (abstract 710). Programs and abstracts of the 2nd International AIDS Society Conference in HIV Pathogenesis and Treatment (Paris), 2003.
14. Katlama C, Gazzard B, Mallolas J, Schurmann D, Moroni M, Demonty N, et al. Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to trizivir vs continued highly active antiretroviral therapy. AIDS 2003; 17: 1855-6.
15. Duncombe C. Reversal of hyperlipidaemia and lipodystrophy in patients switching therapy to nelfinavir. J Acquir Immune Defic Syndr 2000; 24: 78-9.
16. Wensing AM, Reedijk M, Richter C, Boucher CA, Borleffs JC. Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels. AIDS 2001; 15: 2191-3.
17. Lichtenstein K, Clumeck N, Bellos N, Rodriguez C, Estrada V, Gialelis K, et al. Lipid benefits are observed in antiretroviral (ARV)-experienced HIV-infected patients when switched to atazanavir (ATV)-containing regimens. (abstract LB 17). Programs and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment (Paris), 2003.
18. Andersen O, Haugaard SB, Andersen UB, Friis-Moller N, Storgaard H, Volund A, et al. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism 2003; 52: 1343-53.
19. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-9.
20. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16: F1-8.
21. Walli RK, Michl GM, Bogner JR, Goebel FD. Improvement of HAART-associated insulin resistance and dyslipidaemia after replacement of protease inhibitors with abacavir. Eur J Med Res 2001; 6: 413-21.
22. Martinez E, Romeu J, Garcia-Viejo MA, Cruz L, Blanco JL, Negredo E, et al. An open randomized study on the replacement of HIV-1 protease inhibitors by efavirenz in chronically suppressed HIV-1-infected patients with lipodystrophy (abstract 668). Programs and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago), 2001.
23. Martinez E, Garcia-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000; 31: 1266-73.
24. Moyle G, Baldwin C, Mandalia S, Comitis S, Burn P, Gazzard B. Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort. J Acquir Immune Defic Syndr 2001; 28: 399-401.
25. Estrada V, de Villar NG, Larrad MT, Lopez AG, Fernandez C, Serrano-Rios M. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clin Infect Dis 2002; 35: 69-76.
26. Gharakhanian S, Salhi Y, Adda N, Vigouroux. C, Capeau J, Rozenbaum W. Identification of fat redistribution/metabolic anomalies in a cohort treated by 2 NRTIs+1 PI, and absence of significant modification following PI-substitution (abstract 46). Programs and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco), 2000.
27. Lafon, E, Bani Sadr F, Chandemerle C, Melchior JC, de Truchis P, Gregoire V, et al. LIPSTOP Study: evolution of clinical lipodystrophy (LD), blood lipids, visceral (VAT) and subcutaneous (SAT) adipose tissue after switching from protease inhibitor (PI) to efavirenz (EFV) in HIV-1 infected patients (abstract 1535). Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto), 2000.
28. Viciana P, Alarcon A, Martin D, Serrano P, Lopez-Cortes LF, Cordero E, Gomez-Vera MJ. Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitors (PI) to efavirenz (EFV) (abstract 48). Programs and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco), 2000.
29. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-10.
30. Tebas P, Yarasheski K, Henry K, Kane E, Marin E, Simpson J, et al. Evolution of multiple metabolic parameters after switch of protease inhibitors to nevirapine (abstract ThPpB1485). Programs and abstracts of the 13th International Conference on AIDS (Durban, South Africa), 2000.
31. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of 3 abacavir-based substitution approaches in the management of dyslipidaemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33: 22-8.
32. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, et al. Abacavir substitution for nucleoside analogues in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288: 207-15.
33. Polo R, Verdejo J, Gonzalez-Munoz M, Gomez-Cano M, Martinez-Garrido S, Martinez-Rodriguez S, Gonzalez-Lahoz J. Switch to AZT+3TC improves lipodystrophy signs in the presence of protease inhibitors (abstract 2043). Programs and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco), 1999.
34. Saint-Marc T, Partisani M, Poizot-Martin I, Touraine JL. Reversibility of peripheral fat wasting (lipoatrophy) on stopping stavudine therapy (abstract 52). Programs and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco), 2000.
35. Smith DE, Carr A, Law M, Martin A, Hudson J, Hoy J, Cooper DA. Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromizes antiviral control: the PIILR extension study. AIDS 2002; 16: 2489-91.
36. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-52.
37. Petit JM, Duong M, Duvillard L, Piroth L, Grappin M, Verges B, et al. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men wiihout modification of insulin sensitivity: a longitudinal study. Horm Metab Res 2000; 32: 367-72.
38. Echevarria KL, Hardin TC, Smith JA. Hyperlipidaemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33: 859-63.
39. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11: 938-9.
40. van der V, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407-14.
41. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-60.
42. Molina JM, Ferchal F, Rancinan C, Yeni P, Rozenbaum W, Journot V, et al. Once-daily combination of emtricitabine, didanosine, and efavirenz vs continued PI-based HAART in HIV-infected adults with undetectable plasma HIV-RNA: 48-week results of a prospective randomized multicentre trial (ALIZE-ANRS 99) (abstract 551). Programs and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston), 2003.
43. Knechten H, Sturner KH, Hohn C, Braun P. Switch to efavirenz in a protease inhibitor-containing regimen. HIV Clin Trials 2001; 2: 200-4.
44. Bonnet EPP, Yovanovitch JD, Mularczyl MB, Hervé R, Labau E, Perret B, et al. Switching from protease inhibitors to efavirenz does not improve clinical lipodystrophy and hyperlipidaemia in HIV-infected patients (abstract 1538). Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto), 2000.
45. Buisson M, Grappin M, Piroth L, Duong M, Portier H, Chavanet P. Simplified maintenance therapy with NNRTI (nevirapine) in patients with long term suppression of HIV-1 RNA: first results of a cohort study (abstract 1541). Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto), 2000.
46. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001; 27: 229-36.
47. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy AIDS 2000; 14: 807-12.
48. Negredo E, Ribalta J, Paredes R, Ferre R, Sirera G, Ruiz L, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16: 1383-9.
49. Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002; 34: 504-10.
50. Fisac C, Fumero E, Crespo M, Rosón B, Virgili N, Ribera E, et al. A randomized trial of metabolic and body composition changes in patients switching from PI-containing regimens to abacavir (ABC), efavirenz (EFV) or nevirapine (NVP) (abstract 699-T). Programs and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle), 2002.
51. John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33: 29-33.
52. Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001; 15: 1811-22.
53. Lafeuillade A, Clumeck N, Mallolas J, Jaeger H, Livrozet JM, Ferreira, et al. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to trizivir vs continued HAART: the Trizal study. HIV Clin Trials 2003; 4: 37-43.
54. Barreiro P, Camino N, de Mendoza C, Soriano V, Blanco F, Valencia E, Gonzalez-Lahoz J. Maintenance therapy with HU-ddI after complete viral suppression on HAART: results at 48 weeks (abstract 533-M). Programs and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle), 2002.
55. Raffi F, Bonnet B, Ferre V, Esnault JL, Perre P, Reliquet V, et al. Substitution of a non-nucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis 2000; 31: 1274-8.
56. McComsey G, Ward D, Hessenthaler S, File T, Ross S, Hernandez J. CT scan findings at 48 weeks confirm further regression of lipoatrophy (LA) following the substitution of stavudine (d4T) with either abacavir (ABC) or zidovudine (ZVD) (abstract H-1929). Programs and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego), 2002.
57. McComsey G. Zerit-related lipoatrophy is reversible by switching to other NRTI. Programs and abstracts of the 41th Annual Meeting of the Infectious Diseases Society of America (San Diego), 2003.
58. Smith D, Martin A, Carr A, Ringland C, Amin J, Emery S, et al. Continued recovery of subcutaneous fat wasting after switching from thymidine nucleoside analogues to abacavir (abstract LB 18). Programs and abstracts of the 2nd International AIDS Society Conference in HIV Pathogenesis and Treatment (Paris), 2003.
59. Garcia-Benayas T, Blanco F, de la Cruz JJ, Soriano V, Gonzalez-Lahoz J. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. AIDS 2003; 17: 921-4.
60. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 1517-26.
61. Maggiolo F, Migliorino M, Pravettoni G, Rizzi M, Capriolo S, Suter F. Management of PI-aasociated metabolic changes by substitution with efavirenz in virologically controlled HIV+ persons (abstract 34600). Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto), 2000.
62. Becker S, Rachlis A, Gill J, Dejesus E, Pierone G, Kirkland L, et al. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral load: a prospective, randomized, multicentre, open-label study (DMP 049) (abstract 20). Programs and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago), 2000.
63. Doser N, Sudre P, Telenti A, Wietlisbach V, Nicod P, Darioli R, Mooser V. Persistent dyslipidaemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. J Acquir Immune Defic Syndr 2001; 26: 389-90.
64. Badsi ESM, Salord JMS. Switching a protease inhibitor (PI) for a non-nucleosidic reverse transcriptase inhibitor (NNRTI): study of a cohort of 59 HIV patients (abstract 1539). Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto), 2000.
65. Casado JL, Arrizabalaga J, Antala A, Iribarren JA, Moreno A, Dronda F, et al. Long-term efficacy and tolerance of switching the protease inhibitor for non-nucleoside reverse transcriptase inhibitors: a 52-week, multicentre, prospective study (abstract 673). Programs and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago), 2001.
66. Melzi S, Adorni F, Castelnuovo B, Chiesa E, Bongiovanni M, Bini T, et al. Virological and immunological outcome in 109 patients with well controlled viral replication who switched from a PI-including to a PI-sparing regimen (abstract P78). Programs and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV-infection (Athens), 2001.
67. Maggiolo F, Migliorino M, Maserati R, Gregis G, Quinzan G, Ripamonti D, et al. Simplified therapeutic strategies in PI-experienced patients successfully treated with HAART (abstract I-1916). Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto), 2001.
68. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-46.
69. Gonzalez-Benayas T, Blanco F, Gonzalez-Viera J, Soriano V, Gonzalez-Lahoz J. Metabolic effects and lipodystrophy body-shape changes after replacing stavudine by abacavir (abstract H-1928). Programs and abstracts of the 42th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego), 2002.